Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
Domain will attend the 34th JP MORGAN Annual Healthcare Conference on January 10-14, 2016 in San Fransisco, CA (USA)
PeptiMimesis, a breakthrough approach to the development of oncology therapies, from Conectus Alsace’s maturation investments
Domain will attend the BIOFIT 2015 Convention, on December 1-2, 2015 in Strasbourg (France)
Domain will attend the BIO Europe Convention, on November 2-4, 2015 in Munich